Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of inactivated COVID-19 vaccine in HIV-infected patients
ChiCTR2100047769Phase 4Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Jul 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Rate of adverse events, Total antibody levels and 1 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100047769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047769.